CORPORATE PRESENTATION
|
|
- Gervais Wells
- 5 years ago
- Views:
Transcription
1 CORPORATE PRESENTATION June 2017
2 FORWARD LOOKING SAFE HARBOR STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of These statements are often, but not always, made through the use of words or phrases such as anticipates, expects, plans, believes, intends, and similar words or phrases. Such statements involve risks and uncertainties that could cause Checkpoint Therapeutics actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any such statements due to various factors, including the risks and uncertainties inherent in clinical trials, drug development, and commercialization. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forwardlooking statements are qualified in their entirety by this cautionary statement and Checkpoint Therapeutics undertakes no obligation to update these statements, except as required by law. 2
3 CHECKPOINT THERAPEUTICS CORPORATE HIGHLIGHTS Building portfolio of leading-edge immune-enhanced combination cancer therapies Technologies licensed from Dana Farber, Teva, others Primary focus on validated targets $58 million raised in private rounds in 4Q 2015 Went public in 4Q 2016 via Form 10 Quoted on OTCQX with ticker CKPT Application to up-list to Nasdaq under review Majority-controlled sub of Fortress Biotech (FBIO) 3
4 EVOLUTION OF CANCER THERAPY Chemotherapy Targeted therapy Immuno-oncology Immuno-oncology Combinations Not tumor specific Targets all rapidly dividing cells Highly toxic Targets specific genes/proteins found in cancer cells Rapid responses Better tolerated Stimulates immune system to activate against tumor Long-lasting responses in subsets of patients Wide variety of tumors Combination of I/O - targeted therapy or I/O - I/O provides one-two punch Higher response rates The goal of I/O therapy is to engage the immune system (particularly Killer T-Cells) to attack and kill cancer cells 4
5 WHAT WE DO AT CHECKPOINT Acquire, develop, commercialize immune-enhanced combination treatments for patients with solid tumor cancers Two immuno-oncology I/O monoclonal antibodies (mabs) Four targeted anti-cancer agents Collaborate with TG Therapeutics (Nasdaq:TGTX) to develop I/O antibodies in combination with TG s targeted therapies for liquid tumors (e.g. Non-Hodgkin s Lymphoma and CLL) 5
6 PIPELINE Pipeline Compound & Indication Preclinical Phase I Phase II Phase III Originator Immuno- Oncology Agents CK-301 Anti-PD-L1 (Multiple forms of Cancer) CK-302 Anti-GITR (Multiple forms of Cancer) Target Phase 1 3Q 2017 Target IND: 2018 Dana Farber Dana Farber CK-101 EGFR Inhibitor (Lung Cancer) Phase 1/2 ongoing NeuPharma Targeted Anti- Cancer Agents CK-102 PARP Inhibitor (Multiple forms of Cancer) CK-103 BET Inhibitor (Multiple forms of Cancer) Phase 1b planned Target IND: YE 2017 Teva / Cephalon Jubilant Anti-CAIX (Renal cell Carcinoma, CAIX+ solid tumors) Target IND: 2018 Dana Farber 6
7 LARGE POTENTIAL MARKETS Estimated Compound Indication Current Stage Market Size I/O CK-301 (PD-L1) Multiple solid tumors Pre-clinical >$30B CK-302 (GITR) Multiple solid tumors Pre-clinical >$1B Targeted CK-101 (EGFR) EGFR mutant lung cancer Phase 1 >$3B CK-102 (PARP) Multiple solid tumors Phase 1 >$3B CK-103 (BET) Multiple tumors Pre-clinical >$1B Anti-CAIX Renal cell carcinoma Pre-clinical >$500M 7
8 CHECKPOINT STRATEGY Develop first-in-class or best-in-class combination treatments in targeted solid tumor cancers and liquid tumors in collaboration with TGTX Cancer cells Targeted Anti-Cancer Agents Validated targets for anti-cancer therapy e.g., mutant EGFR lung cancer I/O Agents Anti-PD-L1 Additional I/O agents to augment immune system engagement Achieve pricing leverage by owning all component drugs of combination 8
9 I/O AGENTS: CURRENT PIPELINE CK-301 (Anti-PD-L1) mab Removes cancer cells ability to shield themselves from attack by the immune system s killer T-cells Proven technology, widely applicable among tumor types Unlike most other anti-pd-l1s, Checkpoint s retains native features for potentially greater killing power CK-302 (Anti-GITR) mab Up-regulates the activity of killer T-cells to attack cancer cells Designed to be synergistic with anti-pd-l1 9
10 PD-L1 AND EFFECT OF ANTI-PD-L1 ANTIBODIES Tumor cells up-regulate PD-L1, shielding cancer cells by de-activating T-cell responses Y Anti-PD-L1 monoclonal antibody PD-L1 ligand on tumor cells T-Cell T-Cell T-Cell T-Cell T-Cell T-Cell T-Cell T-Cell Anti-PD-L1 mabs block PD-L1 binding to PD-1 and B7.1, allowing the immune system s T-cells to attack the cancer Cancer cells 10
11 T Cell-Specific Transcription F o l d i n c r e a s e o v e r b c k g r d (Fold increase) CK-301: PRE-CLINICAL ACTIVITY CK-301 potency similar to competitor anti-pd-l1 antibodies in PD-1/PD-L1 blockade bioassay (reversing T-Cell inhibition) 8 6 a t e z o l i z u m a b * d u r v a l u m a b * l o w a f f i n i t y a n t i - P D - L 1 c o n t r o l a v e l u m a b * C K N o r m a l I g G 1 c o n t r o l A n t i b o d y, g / m l Poster: AACR Annual Meeting 2017 * surrogate 11
12 GITR AND EFFECT OF ANTI-GITR ANTIBODIES In addition to the tumor s defense, the immune system may also block T-Cells from attacking the cancer Anti-GITR antibodies are believed to be able to block T-reg function, permitting T-cells to attack the cancer Y Anti-GITR monoclonal antibody GITR ligand on T-reg cells T-REG T-REG T-REG T-REG T-Cell T-Cell T-Cell T-Cell T-Cell T-Cell T-Cell T-Cell Cancer cells 12
13 I/O AGENTS: CURRENT STATUS CK-301 (Anti-PD-L1) Phase 1 initiation targeted for 3Q 2017 CK-302 (Anti-GITR) IND-enabling program ongoing IND targeted for 2018 Other I/O targeted agents in exploratory stages 13
14 TARGETED ANTI-CANCER THERAPIES Goal of targeted anti-cancer therapy is to smart bomb specific cancer pathways or driver mutations Pipeline Compound & Indication Preclinical Phase I Phase II Phase III CK-101 EGFR Inhibitor (Lung Cancer) Phase 1/2 ongoing CK-102 PARP Inhibitor (Multiple forms of Cancer) CK-103 BET Inhibitor (Multiple forms of Cancer) Phase 1b planned Target IND: YE 2017 Four unique mechanisms for targeting cancer cells Anti-CAIX (Renal cell Carcinoma, CAIX+ solid tumors) Target IND:
15 CK-101: 3 RD GENERATION EGFR INHIBITOR RATIONALE EGFR Mutations Validated Target Success of 1 st generation EGFR s have led to acquired resistance through further mutations to EGFR (T790M) One 3 rd generation EGFR inhibitor (Tagrisso ) is approved for patients with lung cancer with T790M mutation Est. peak sales: $3 billion CK-101 has potential safety advantages Tagrisso has significant skin tox due to also inhibiting wild-type EGFR CK-101 has limited targeting of wild-type 15
16 CK-101: 3 RD GENERATION EGFR INHIBITOR PRE-CLINICAL EFFICACY In vitro, CK-101 showed: Strong efficacy for T790M and other EGFR mutations Good selectivity for mutant over wild-type EGFR A431/H1975 ratio ~ 100 fold Target profile: Strong efficacy and tolerability IC 50 (nm) Cell Line H1975 HCC827 A431 Mutation L858R/T790M Exon 19 del EGFR WT Afatinib Tagrisso CK Poster: AACR Annual Meeting
17 CK-101: 3 RD GENERATION EGFR INHIBITOR PRE-CLINICAL EFFICACY In mice, CK-101 showed strong activity against T790M mutant NSCLC with increasing dose. Vehicle Control T790M NSCLC xenograft model CK mg/kg Afatinib 20 mg/kg CK mg/kg CK mg/kg Poster: AACR Annual Meeting
18 CK-101: 3 RD GENERATION EGFR INHIBITOR PRE-CLINICAL EFFICACY In mice, CK-101 showed no activity against wild-type EGFR with increasing dose. Vehicle Control, 0 mg/kg CK-101, 50 mg/kg CK-101, 100 mg/kg CK-101, 200 mg/kg WT EGFR xenograft model Afatinib, 6 mg/kg Poster: AACR Annual Meeting
19 CK-101: PHASE 1/2 CLINICAL STUDY NSCLC T790M MUTATION-POSITIVE PATIENTS Phase 1 dose escalation ongoing to identify Phase 2 dose Phase 2 will confirm safety and efficacy profile Enrollment expected to begin by year-end 2017 ~60 NSCLC T790M mutation-positive patients Mutation confirmed by Roche diagnostic to rule out non-responders Primary endpoint: Objective response rate (ORR) Plan to develop as a monotherapy and in combination with synergistic I/O agents 19
20 CK-101 EXPECTED PHASE 3 STUDY DESIGN SIMILAR DESIGN AS USED BY TAGRISSO Open-label, randomized study of CK-101 vs platinum-based doublet chemotherapy in 2 nd line EGFR T790M mutation-positive NSCLC, following progression on a 1 st generation EGFR inhibitor Patients pre-screened for T790M mutation Primary endpoint: Progression-free survival Tagrisso : 419 patients, 2:1 ratio; PFS 10.1 months vs 4.4 months (chemo); patients crossed over after progression. Est. enrollment of 200 pts CK-101 vs 100 pts chemo and allow crossover post-progression Target initiation of Phase 3 by YE 2018; ~18-24 months to enroll and reach PFS endpoint 20
21 ANNUAL INCIDENCE OF NSCLC WITH T790M MUTATION MAJOR MARKETS Type U.S. E.U. Japan NSCLC Annual Incidence 190, ,000 80,000 EGFR Mutations L858R, del(19) 19,000 26,000 24,000 T790M Resistant 11,000 15,000 14,000 Est. Annual Incidence: ~40,000 patients Sources: American Cancer Society; GLOBOCAN, Jeffrey A Engelman, et al., Clinical Cancer Research,
22 ADDITIONAL TARGETED ANTI-CANCER AGENTS CK-102 (PARPi) Oral, small molecule inhibitor of PARP, an enzyme essential for DNA repair PARP inhibitors have activity in multiple tumors (breast, ovarian, prostate), particularly those with existing DNA repair defects: BRCA1 and BRCA2 Re-formulating for Phase 1b clinical study CK-103 (BETi) Oral, small molecule inhibitor of the BET protein, BRD4 BRD4 is often required for expression of c-myc oncogene, a growth promoting transcription factor Inhibition of BET can lead to selective killing of tumor cells Targeting IND filing YE 2017 Anti-CAIX mab For CAIX+ RCC and other CAIX+ solid tumors CAIX overexpressed in over 85% of RCC Glycoengineering to enhance ADCC activity; potential synergy with anti-pd-l1 22
23 COLLABORATION WITH TG THERAPEUTICS Joint development of anti-pd-l1, anti-gitr, and BET inhibitor programs Checkpoint to develop in solid tumor indications and TG to develop in liquid tumors Checkpoint is eligible for royalties and milestones 23
24 KEY TAKEAWAYS Building a platform to combine targeted agents with I/O agents to maximize anti-cancer effect On-going: CK-101 (EGFR) Phase 1/2 study 3Q17: CK-301 (anti-pd-l1) Phase 1 initiation Four additional agents in portfolio Large potential market opportunities based on reasonably sized registration studies Funded with cash to support development programs through
25 CORPORATE PRESENTATION June 2017
Corporate Presentation March 2016
Corporate Presentation March 2016 Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationTarGeting B-Cell Diseases
TarGeting B-Cell Diseases Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements
More informationEarly in the Clinic, But Drugging Proven Targets Reduces Risk and Hastens Pace of Development: Initiating BUY/$18 TP
Checkpoint Therapeutics, Inc. May 18, 2017 BUY (OTCQX: CKPT, $10.75) Early in the Clinic, But Drugging Proven Targets Reduces Risk and Hastens Pace of Development: Initiating BUY/$18 TP Jonathan Aschoff,
More informationNASDAQ: TGTX. 33 rd Annual JP Morgan Healthcare Conference
NASDAQ: TGTX 33 rd Annual JP Morgan Healthcare Conference January 2015 Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities
More informationLeerink Immuno-Oncology Roundtable Conference
Leerink Immuno-Oncology Roundtable Conference September 28, 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 3Q 2018 EARNINGS PRESENTATION NOVEMBER 2018 1 Forward-looking statements disclosure This presentation
More informationNASDAQ: TGTX Jefferies Healthcare Conference June 2015
NASDAQ: TGTX Jefferies Healthcare Conference June 2015 Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation
More information33 rd Annual J.P. Morgan Healthcare Conference. January 2015
33 rd Annual J.P. Morgan Healthcare Conference January 2015 Forward-looking Statements This presentation contains forward-looking statements, which express the current beliefs and expectations of management.
More informationWells Fargo Healthcare Conference September 6, 2018
Wells Fargo Healthcare Conference September 6, 2018 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they are
More informationInvestor Call. May 19, Nasdaq: IMGN
Investor Call May 19, 2017 Nasdaq: IMGN Forward-Looking Statements This presentation includes forward-looking statements based on management's current expectations. These statements include, but are not
More informationFive Prime Therapeutics, Inc. Corporate Overview
Five Prime Therapeutics, Inc. Corporate Overview June 2015 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities
More informationSavolitinib Global Phase II Trial Initiated in EGFR Mutant Non-Small Cell Lung Cancer
Savolitinib Global Phase II Trial Initiated in EGFR Mutant Non-Small Cell Lung Cancer Initiation of expanded Phase II trials in NSCLC triggers US$10 million milestone from AstraZeneca to Chi-Med New study
More informationADAPTIMMUNE INVESTOR PRESENTATION. August 2016
ADAPTIMMUNE INVESTOR PRESENTATION August 2016 DISCLAIMER This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),
More informationCorporate Presentation May Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers
Corporate Presentation May 2016 Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers Forward-looking statements / safe harbor This presentation and the accompanying oral commentary contain
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer January 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results
More informationCorporate Presentation October 2018 Nasdaq: ADXS
Innovations in Immuno-Oncology Corporate Presentation October 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements
More informationCombining HS-110 and anti-pd-1 in NSCLC. September 1, 2015
Combining HS-110 and anti-pd-1 in NSCLC September 1, 2015 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases, these forward-looking
More informationJuly, ArQule, Inc.
July, 2012 Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to clinical
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer March 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward-looking statements. Rexahn's actual results may
More informationOncology Therapeutics without Compromise APRIL 2011
Oncology Therapeutics without Compromise APRIL 2011 Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties, including among other
More informationONO PHARMACEUTICAL CO., LTD. and Bristol-Myers Squibb Announce Strategic Immuno-Oncology Collaboration in Japan, South Korea and Taiwan
ONO PHARMACEUTICAL CO., LTD. and Bristol-Myers Squibb Announce Strategic Immuno-Oncology Collaboration in Japan, South Korea and Taiwan Companies to develop and commercialize Opdivo (nivolumab), ipilimumab,
More informationVAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients. September 2018
VAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients September 2018 Forward-Looking Statements Any statements contained in this presentation that do not describe historical facts may
More informationArQule Jefferies Global Healthcare Conference June 2015
ArQule Jefferies Global Healthcare Conference June 2015 1 ArQule Corporate Update Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning
More informationNational Bank 8th Annual Quebec Conference TSX: IMV. May 30, IMV Inc. All rights reserved.
National Bank 8th Annual Quebec Conference TSX: IMV May 30, 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV Inc.
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer June 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results may
More informationNASDAQ: TGTX. J.P. Morgan Healthcare Conference January 2017
NASDAQ: TGTX J.P. Morgan Healthcare Conference January 2017 Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation
More informationASCO 2018 Investor Meeting
ASCO 2018 Investor Meeting June 4, 2018 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute forward-looking statements for
More informationTARGET A BETTER NOW FORWARD-LOOKING STATEMENTS NASDAQ: IMGN. Current as of January 2018
NASDAQ: IMGN TARGET A BETTER NOW Current as of January 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward looking statements based on management's current expectations. These statements
More informationFirst Phase 3 Results Presented for a PD-1 Immune Checkpoint Inhibitor
September 30, 2014 Positive Phase 3 Data for Opdivo (nivolumab) in Advanced Melanoma Patients Previously Treated with Yervoy @ (ipilimumab) Presented at the ESMO 2014 Congress First Phase 3 Results Presented
More informationDawson James Conference
Dawson James Conference October 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations regarding
More informationCiti s 13 th Annual Biotech Conference September 5, 2018
Citi s 13 th Annual Biotech Conference September 5, 2018 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they
More informationArQule CorporateUpdate
ArQule April 2015 1 ArQule CorporateUpdate Safe Harbor This presentation and other statements by ArQule may contain forwardlooking statements within the meaning of the Private Securities Litigation Reform
More informationCorporate Presentation September Nasdaq: ADXS
Corporate Presentation September 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements regarding the ability and
More informationCorporate Overview May 8, 2014
0 Corporate Overview May 8, 2014 NASDAQ: CRIS Forward Looking Statements This presentation contains statements about Curis future expectations, plans and prospects that constitute forward-looking statements
More informationCorporate Overview. June 2017 NASDAQ:FPRX
Corporate Overview June 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of
More informationTargeting the genetic and immunological drivers of cancer
NASDAQ: MRTX Targeting the genetic and immunological drivers of cancer Corporate Presentation April 2019 1 Safe Harbor Statement Certain statements contained in this presentation, other than statements
More informationMarch Corporate Presentation
March 2017 Corporate Presentation Disclaimer This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements
More informationBreakthrough Cancer Therapies: Directing the Immune System to Eliminate Tumor Cells. Corporate Presentation June 2015
Breakthrough Cancer Therapies: Directing the Immune System to Eliminate Tumor Cells Corporate Presentation June 2015 Forward-looking statements / safe harbor This presentation and the accompanying oral
More informationNewLink Genetics Corporation
Cantor Fitzgerald 2018 Global Healthcare Conference NewLink Genetics Corporation NASDAQ: NLNK October 3, 2018 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking
More informationDetermined to realize a future in which people with cancer live longer and better than ever before Q Conference Call
Reimagining Cancer Treatment Determined to realize a future in which people with cancer live longer and better than ever before Q1 2016 Conference Call 1 Forward-Looking Statements Disclosure This presentation
More information2016 Year-End Results and Conference Call. March 14, 2017
2016 Year-End Results and Conference Call March 14, 2017 Forward Looking Statement This communication contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform
More informationDetermined to realize a future in which people with cancer live longer and better than ever before 4Q18 EARNINGS PRESENTATION MARCH 2019
Determined to realize a future in which people with cancer live longer and better than ever before 4Q18 EARNINGS PRESENTATION MARCH 2019 Forward-looking statements disclosure This presentation contains
More informationCorporate Presentation June Curis, Inc All Rights Reserved
Corporate Presentation June 2018 Curis, Inc. 2018 All Rights Reserved Forward Looking Statements This presentation contains certain forward-looking statements about Curis, Inc. ( we, us, or the Company
More informationAVEO Oncology Announces Strategic Restructuring. AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET
NEWS RELEASE FOR IMMEDIATE RELEASE AVEO Oncology Announces Strategic Restructuring AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET CAMBRIDGE, Mass., June 4, 2013 AVEO Oncology (NASDAQ: AVEO)
More informationNYSE AMER: MTNB. MAT9001 OVERVIEW. September 2018
NYSE AMER: MTNB www.matinasbiopharma.com MAT9001 OVERVIEW September 2018 1 Forward Looking Statement This presentation contains "forward-looking statements" within the meaning of the Private Securities
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer September 2013 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results
More informationPositioned for Growth
Positioned for Growth Annual Shareholders Meeting July 21, 2016 Paris Panayiotopoulos President and Chief Executive Officer David Sachs Non small cell lung cancer ARIAD clinical trial patient This presentation
More informationMerck ASCO 2015 Investor Briefing
Merck ASCO 2015 Investor Briefing Forward-Looking Statement This presentation includes forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation
More informationInducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy
Inducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy Company Overview, September 2018 Safe Harbor Statement This presentation contains forward-looking
More informationInvestor Webcast: Initial Data from Phase 1a/1b Trial of Cabiralizumab/OPDIVO and Early Efficacy Signal in Pancreatic Cancer.
Investor Webcast: Initial Data from Phase 1a/1b Trial of Cabiralizumab/OPDIVO and Early Efficacy Signal in Pancreatic Cancer November 8, 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation
More informationCorporate Presentation. Curis, Inc All Rights Reserved
Corporate Presentation Curis, Inc. 2018 All Rights Reserved Forward Looking Statements This presentation contains certain forward-looking statements about Curis, Inc. ( we, us, or the Company ) within
More informationARQ 087 Overview. FGFR Inhibitor. March 2017
ARQ 087 Overview FGFR Inhibitor March 2017 Safe Harbor This presentation and other statements by ArQule contain forward-looking statements within the meaning of the Private Securities Litigation Reform
More informationAmicus Establishes Gene Therapy Pipeline for Lysosomal Storage Disorders (LSDs) Conference Call and Webcast September 20, 2018
Amicus Establishes Gene Therapy Pipeline for Lysosomal Storage Disorders (LSDs) Conference Call and Webcast September 20, 2018 Introduction 2 Safe Harbor This presentation contains "forward-looking statements"
More informationCOMPANY OVERVIEW. June CytomX Therapeutics, Inc.
COMPANY OVERVIEW June 2016 2016 CytomX Therapeutics, Inc. Forward Looking Statements Special Note Regarding Forward-Looking Statements This presentation may contain projections and other forward-looking
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 1Q 2018 EARNINGS PRESENTATION MAY 2018 1 Forward-looking statements disclosure This presentation contains
More informationThe Next Generation of Immunotherapy Platforms. 36 th Annual J.P. Morgan Healthcare Conference January 2018
The Next Generation of Immunotherapy Platforms 36 th Annual J.P. Morgan Healthcare Conference January 2018 Forward-Looking Statements This presentation contains certain forward-looking information about
More informationBeyond PARP - Next Generation DDR Therapeutics
Beyond PARP - Next Generation DDR Therapeutics September 19, 2017 Safe Harbor Statement Except for statements of historical fact, any information contained in this presentation may be a forward-looking
More informationARIAD Pharmaceuticals, Inc.
ARIAD Pharmaceuticals, Inc. June 8, 2016 David Sachs Non-small cell lung cancer 1 ARIAD clinical trial patient Some of the statements in this presentation constitute forward looking statements under the
More informationA targeted oncology company developing a pipeline of cancer therapies for select patient populations.
A targeted oncology company developing a pipeline of cancer therapies for select patient populations. JEFFERIES GLOBAL HEALTHCARE CONFERENCE CHARLES BAUM, M.D., PH.D., PRESIDENT AND CEO JUNE 2015 Safe
More informationQ Financial Update November 6, 2018 NASDAQ:FPRX
Q3 2018 Financial Update November 6, 2018 NASDAQ:FPRX 2 Forward-Looking Statements Disclaimer Forward-looking statements contained in this presentation include statements regarding (i) the timing of initiation,
More informationInvestor Meetings October 2018
Investor Meetings October 2018 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they are forward-looking statements
More informationNovel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates
Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates Christopher Turner, MD Vice President, Clinical Science 04 November 2016 Uveal Melanoma Celldex Pipeline CANDIDATE INDICATION Preclinical
More informationThird Quarter 2018 Financial Results. November 1, 2018
Third Quarter 2018 Financial Results November 1, 2018 Agios Conference Call Participants Prepared Remarks Introduction RENEE LECK, Associate Director, Investor Relations Business Highlights & 2018 Key
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 4Q 2017 EARNINGS PRESENTATION MARCH 2018 1 Forward-looking statements disclosure This presentation contains
More informationNext Generation DDR Therapeutics
Next Generation DDR Therapeutics Q3 2018 Safe Harbor Statement Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects
More informationCelldex Provides Corporate Update and Reports First Quarter 2018 Results
May 10, 2018 Celldex Provides Corporate Update and Reports First Quarter 2018 Results HAMPTON, N.J., May 10, 2018 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and
More informationMore cancer patients are being treated with immunotherapy, but
Bristol-Myers Squibb and Five Prime Present Phase 1a/1b Data Evaluating Cabiralizumab (anti-csf-1 receptor antibody) with Opdivo (nivolumab) in Patients with Advanced Solid Tumors PRINCETON, N.J. & SOUTH
More informationGSK Oncology R&D Update
GSK Oncology R&D Update Axel Hoos, MD Senior Vice President, Oncology R&D February 2019 Cautionary statement regarding forward-looking statements This presentation may contain forward-looking statements.
More informationCompany Overview. April Rewriting cancer treatment NASDAQ: EPZM
Company Overview NASDAQ: EPZM Rewriting cancer treatment Forward Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform
More informationMERCK ONCOLOGY OVERVIEW AACR 2018 APRIL 16, 2018
MERCK ONCOLOGY OVERVIEW AACR 2018 APRIL 16, 2018 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the company ) includes
More informationClovis Oncology Announces First Quarter 2017 Operating Results. May 3, :06 PM ET
Clovis Oncology Announces First Quarter 2017 Operating Results May 3, 2017 4:06 PM ET Strong Q1 launch quarter for Rubraca (rucaparib) in U.S. with $7M reported in net sales Clovis notified that ARIEL3
More informationMERCK ONCOLOGY OVERVIEW ASCO 2018 JUNE 4, 2018
MERCK ONCOLOGY OVERVIEW ASCO 218 JUNE 4, 218 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the company ) includes forward
More informationBeyond PARP - Next Generation DDR Therapeutics
Beyond PARP - Next Generation DDR Therapeutics Q1 2017 Safe Harbor Statement Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement
More informationJune IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs)
June 2015 IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs) 1 Forward-looking Statements This presentation contains forward-looking statements with respect to, among other things, our
More informationCorporate Presentation: 2018 Wedbush PacGrow Healthcare Conference August 14, 2018
Corporate Presentation: 2018 Wedbush PacGrow Healthcare Conference August 14, 2018 2018 CytomX Therapeutics, Inc. 1 Forward Looking Statements Special Note Regarding Forward-Looking Statements This presentation
More informationFORWARD II PROGRAM UPDATE
FORWARD II PROGRAM UPDATE NASDAQ: IMGN May 17, 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements based on management's current expectations. These statements include,
More informationBusiness Update & Financial Results for Q1 2018
Business Update & Financial Results for Q1 2018 May 15, 2018 Disclaimer The statements made in this presentation may include forward-looking statements regarding the future operations of ERYTECH Pharma
More informationTranslating cancer biology into medicines BIO CEO Investor Conference NASDAQ CYCC - February 12, 2018
CYC 682 Translating cancer biology into medicines BIO CEO Investor Conference NASDAQ CYCC - February 12, 2018 Disclaimer This presentation contains forward-looking statements within the meaning of the
More informationCorporate Presentation
Corporate Presentation Leerink Global Healthcare Conference February 14 th -15 th, 2018 C O N F I D E N T I A L a n d P R O P R I E T A R Y Forward Looking Statements / Safe Harbor This presentation contains
More informationREWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES
REWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES May 18, 2017 Molecularly Defined Solid Tumor Program Update FORWARD-LOOKING STATEMENTS Any statements in this press release about future expectations,
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 4Q 2016 EARNINGS PRESENTATION MARCH 2017 1 Forward-looking statements disclosure This presentation contains
More informationNext Generation DDR Therapeutics
Next Generation DDR Therapeutics Q1 2018 Safe Harbor Statement Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects
More informationVeriStrat Poor Patients Show Encouraging Overall Survival and Progression Free Survival Signal; Confirmatory Phase 2 Study Planned by Year-End
AVEO and Biodesix Announce Exploratory Analysis of VeriStrat-Selected Patients with Non-Small Cell Lung Cancer in Phase 2 Study of Ficlatuzumab Presented at ESMO 2014 Congress VeriStrat Poor Patients Show
More informationCorporate Presentation: Jefferies Global Healthcare Conference June 7, 2018
Corporate Presentation: Jefferies Global Healthcare Conference June 7, 2018 2018 CytomX Therapeutics, Inc. 1 Forward Looking Statements Special Note Regarding Forward-Looking Statements This presentation
More informationNASDAQ: CYTR FIGHTING CANCER WITH CUTTING EDGE SCIENCE. Corporate Overview. July 2018
NASDAQ: CYTR Corporate Overview July 2018 CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER MATERIALLY
More informationDeveloping & Commercializing Targeted Small Molecule Drugs in Cancer
Developing & Commercializing Targeted Small Molecule Drugs in Cancer SAFE HARBOR STATEMENT 2 Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions
More informationCorporate Presentation November Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers
Corporate Presentation November 2015 Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers Forward-looking statements / safe harbor This presentation and the accompanying oral commentary
More informationCapricor Therapeutics
Therapeutics Conference Call to Discuss the HOPE-2 Clinical Trial NASDAQ: CAPR November 29, 2017 Forward-Looking Statements Statements in this presentation regarding the efficacy, safety, and intended
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics. Jefferies 2015 Global Healthcare Conference Peter P. Pfreundschuh, VP Finance and CFO
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Jefferies 2015 Global Healthcare Conference Peter P. Pfreundschuh, VP Finance and CFO Forward-Looking Statements This
More informationDicerna Pharmaceuticals Overview. Delivering RNAi-Based Breakthrough Therapies
Pharmaceuticals Overview Delivering RNAi-Based Breakthrough Therapies Forward-Looking Statements This information may contain projections and other forward looking statements regarding future events, including
More informationUnder the terms of the agreement, AVEO will receive an initial cash payment of $125 million, composed of a $75 million license fee and $50 million in
Astellas Pharma Inc. AVEO Pharmaceuticals Corporate Communications Investor Contact: Astellas Pharma Inc. Monique Allaire AVEO Pharmaceuticals +81(3)-3244-3201 (617) 299-5810 Media Contact: Dan Budwick
More informationRXi Pharmaceuticals. Immuno-Oncology World Frontiers Conference. January 23, 2018 NASDAQ: RXII. Property of RXi Pharmaceuticals
RXi Pharmaceuticals Immuno-Oncology World Frontiers Conference January 23, 2018 NASDAQ: RXII Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private
More informationForward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements, including statements related to Seattle Genetics corporate priorities, financial guidance and anticipated upcoming activities,
More information2018 Bank of America Merrill Lynch Healthcare Conference
CHANGING THE COURSE OF HUMAN HEALTH THROUGH BOLD PURSUITS IN SCIENCE 2018 Bank of America Merrill Lynch Healthcare Conference May 16, 2018 Forward-Looking Statements and Adjusted Financial Information
More informationDetermined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION SEPTEMBER 2017
Determined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION SEPTEMBER 2017 1 Forward-looking statements disclosure This presentation contains
More informationSpectrum Pharmaceuticals
Spectrum Pharmaceuticals Joe Turgeon President and CEO June 2018 Investor Presentation 1 Safe Harbor Statement This presentation contains forward looking statements regarding future events and the future
More informationExpertly targeting drivers of cancer in select patient populations. June 2016
Expertly targeting drivers of cancer in select patient populations v June 2016 Safe Harbor Statement Certain statements contained in this presentation, other than statements of fact that are independently
More informationNew Generation of T-cell Therapeutics
New Generation of T-cell Therapeutics Corporate Overview January 2017 NASDAQ: TPIV 1 Safe Harbor Statement Certain statements contained herein are forward-looking statements within the meaning of the safe
More informationDetermined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION JUNE 2017
Determined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION JUNE 2017 1 Forward-looking statements disclosure This presentation contains forward-looking
More informationCorporate Overview. June 2018 NASDAQ:FPRX
Corporate Overview June 2018 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of
More information